AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Cancer immunotherapy is an artificial stimulation of the immune system to recognize cancer cells and activate specific immune cells to target and attack cancer cells. In clinical trials, immunotherapy has recently shown impressive results in the treatment of multiple cancers. Thus, cancer immunotherapy has gained a lot of attention for its unique advantages and promising future. With extensive research on cancer immunotherapy, its safety and effectiveness has gradually been revealed. However, it is still a huge challenge to expand and drive this therapy while maintaining low toxicity, high specificity, and long-lasting efficacy. As a unique technology, nanotechnology has been applied in many fields, the advantages of which will promote the development of cancer immunotherapies. Researchers have tried to apply nanomaterials to cancer immunotherapy due to their advantageous properties, such as large specific surface areas, effective drug delivery, and controlled surface chemistry, to improve treatment efficacy. Here, we briefly introduce the current applications of nanomaterials in cancer immunotherapy, including adoptive cell therapy (ACT), therapeutic cancer vaccines, and monoclonal antibodies, and throw light on future directions of nanotechnology-based cancer immunotherapy.
McCarthy EF. The toxins of william b. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006; 26: 154-8.
Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014; 20: 1657-66.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371: 1507-17.
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29: 917-24.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-t immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-22.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-84.
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, et al. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 2014; 3: e27048.
Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015; 15: 361-70.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373: 123-35.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521-32.
Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014; 20: 119-22.
van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJM. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer. 2016; 16: 219-33.
Wang C, Ye YQ, Hu QY, Bellotti A, Gu Z. Tailoring biomaterials for cancer immunotherapy: emerging trends and future outlook. Adv Mater. 2017; 29: 1606036.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60.
Smith MJ, Brown JM, Zamboni WC, Walker NJ. From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system. Toxicol Sci. 2014; 138: 249-55.
Kapadia CH, Perry JL, Tian SM, Luft JC, DeSimone JM. Nanoparticulate immunotherapy for cancer. J Control Release. 2015; 219: 167-80.
Manjili HK, Malvandi H, Mousavi MS, Attari E, Danafar H. In vitro and in vivo delivery of artemisinin loaded PCL-PEG-PCL micelles and its pharmacokinetic study. Artif Cells Nanomed Biotechnol. 2018; 46: 926-36.
Koshy ST, Mooney DJ. Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol. 2016; 40: 1-8.
Moon JJ, Huang B, Irvine DJ. Engineering nano- and microparticles to tune immunity. Adv Mater. 2012; 24: 3724-46.
Song WT, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017; 148: 16-30.
Chen DS, Mellman I. Oncology meets immunology: the cancerimmunity cycle. Immunity. 2013; 39: 1-10.
Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012; 2: 3-44.
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5: 505-15.
Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immunology. Nat Rev Immunol. 2013; 13: 592-605.
Mahjub R, Jatana S, Lee SE, Qin Z, Pauli G, Soleimani M, et al. Recent advances in applying nanotechnologies for cancer immunotherapy. J Control Release. 2018; 288: 239-63.
Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, et al. CD40-targeted dendritic cell delivery of PLGAnanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015; 40: 88-97.
Yuba E, Yamaguchi A, Yoshizaki Y, Harada A, Kono K. Bioactive polysaccharide-based pH-sensitive polymers for cytoplasmic delivery of antigen and activation of antigen-specific immunity. Biomaterials. 2017; 120: 32-45.
Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines. 2011; 10: 1569-83.
Hassan HAFM, Smyth L, Wang JTW, Costa PM, Ratnasothy K, Diebold SS, et al. Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. Biomaterials. 2016; 104: 310-22.
Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu ZS, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006; 23: 1574-85.
Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, et al. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 2018; 164: 38-53.
Amoozgar Z, Goldberg MS. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. Adv Drug Deliv Rev. 2015; 91: 38-51.
Daftarian P, Kaifer AE, Li W, Blomberg BB, Frasca D, Roth F, et al. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. Cancer Res. 2011; 71: 7452-62.
Jeanbart L, Kourtis IC, van der Vlies AJ, Swartz MA, Hubbell JA. 6-thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T Cell immunotherapy in tumor-bearing mice. Cancer Immunol Immunother. 2015; 64: 1033-46.
Luo ZC, Wang C, Yi HQ, Li P, Pan H, Liu LL, et al. Nanovaccine loaded with poly I:C and STAT3 sirna robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo. Biomaterials. 2015; 38: 50-60.
Thomann-Harwood LJ, Kaeuper P, Rossi N, Milona P, Herrmann B, McCullough KC. Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation. J Control Release. 2013; 166: 95-105.
Tang L, Zheng YR, Melo MB, Mabardi L, Castaño AP, Xie YQ, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018; 36: 707-16.
Koshy ST, Cheung AS, Gu L, Graveline AR, Mooney DJ. Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy. Adv Biosyst. 2017; 1: 1600013.
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016; 534: 396-401.
Romagnoli GG, Zelante BB, Toniolo PA, Migliori IK, Barbuto JAM. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front Immunol. 2015; 5: 692.
Almeida JPM, Figueroa ER, Drezek RA. Gold nanoparticle mediated cancer immunotherapy. Nanomedicine. 2014; 10: 503-14.
Choi WI, Lee JH, Kim JY, Heo SU, Jeong YY, Kim YH, et al. Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab. Nanomedicine. 2015; 11: 359-68.
Guo HC, Feng XM, Sun SQ, Wei YQ, Sun DH, Liu XT, et al. Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein. Virol J. 2012; 9: 108.
Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008; 60: 1278-88.
Wang C, Xu LG, Liang C, Xiang J, Peng R, Liu Z. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater. 2014; 26: 8154-62.
Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 2016; 11: 295-303.
Waeckerle-Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev. 2005; 57: 475-82.
Heo MB, Lim YT. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials. 2014; 35: 590-600.
Kokate RA, Chaudhary P, Sun XL, Thamake SI, Maji S, Chib R, et al. Rationalizing the use of functionalized poly-lactic-coglycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Nanomedicine (Lond). 2016; 11: 479-94.
García-Vallejo JJ, Ambrosini M, Overbeek A, van Riel WE, Bloem K, Unger WWJ, et al. Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells. Mol Immunol. 2013; 53: 387-97.
Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007; 65: 259-69.
Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett. 2017; 190: 64-83.
Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater. 2012; 11: 895-905.
Sugiyama I, Sadzuka Y. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin. Int J Pharm. 2013; 441: 279-84.
Yuba E, Kanda Y, Yoshizaki Y, Teranishi R, Harada A, Sugiura K, et al. pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon-γ gene lipoplex for efficient cancer immunotherapy. Biomaterials. 2015; 67: 214-24.
Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One. 2008; 3: e3377.
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cellfree vaccine: dendritic cell derived exosomes. Nat Med. 1998; 4: 594-600.
Lin AY, Almeida JPM, Bear A, Liu N, Luo L, Foster AE, et al. Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One. 2013; 8: e63550.
Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol. 2011; 6: 675-82.
Hanafi-Bojd MY, Ansari L, Malaekeh-Nikouei B. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles. Ther Deliv. 2016; 7: 649-55.
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314: 126-9.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298: 850-4.
Rezvani K, Rouce R, Liu EL, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017; 25: 1769-81.
Locatelli F, Moretta F, Brescia L, Merli P. Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol. 2014; 26: 173-9.
Davila ML, Brentjens R, Wang XY, Rivière I, Sadelain M. How do CARs work? Early insights from recent clinical studies targeting CD19 Oncoimmunology. 2012; 1: 1577-83.
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127: 3321-30.
Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013; 21: 904-12.
Zhang Q, Zhang HX, Ding JG, Liu HY, Li HZ, Li HL, et al. Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. J Immunol Res. 2018; 2018: 4263520.
Matosevic S. Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies. J Immunol Res. 2018; 2018: 4054815.
Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015; 33: 97-101.
Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010; 16: 1035-41.
Zheng YR, Stephan MT, Gai SA, Abraham W, Shearer A, Irvine DJ. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. J Control Release. 2013; 172: 426-35.
Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji WH, Reiman D, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017; 12: 813-20.
Gatti-Mays ME, Redman JM, Collins JM, Bilusic M. Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother. 2017; 13: 2561-74.
Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine. 2012; 30: 142-54.
Xia YF, Fan QZ, Hao DX, Wu J, Ma GH, Su ZG. Chitosan-based mucosal adjuvants: sunrise on the ocean. Vaccine. 2015; 33: 5997-6010.
van Riet E, Ainai A, Suzuki T, Kersten G, Hasegawa H. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design. Adv Drug Deliv Rev. 2014; 74: 28-34.
Hamdy S, Molavi O, Ma ZS, Haddadi A, Alshamsan A, Gobti Z, et al. Co-delivery of cancer-associated antigen and toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine. 2008; 26: 5046-57.
Ahn S, Lee IH, Kang S, Kim D, Choi M, Saw PE, et al. Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy. Adv Healthc Mater. 2014; 3: 1194-9.
Li HY, Li YH, Jiao J, Hu HM. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol. 2011; 6: 645-50.
Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-Ⅰ presentation by dendritic cells and macrophages in vitro. Vaccine. 2003; 21: 1250-5.
Anderson PM, Hanson DC, Hasz DE, Halet MR, Blazar BR, Ochoa AC. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-γ. Cytokine. 1994; 6: 92-101.
Curnis F, Fiocchi M, Sacchi A, Gori A, Gasparri A, Corti A. NGRtagged nano-gold: a new CD13-selective carrier for cytokine delivery to tumors. Nano Res. 2016; 9: 1393-408.
Wang Y, Lin YX, Qiao SL, An HW, Ma Y, Qiao ZY, et al. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials. 2017; 112: 153-63.
Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008; 8: 108-20.
Li SY, Liu Y, Xu CF, Shen S, Sun R, Du XJ, et al. Restoring antitumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. J Control Release. 2016; 231: 17-28.
Rahimian S, Fransen MF, Kleinovink JW, Christensen JR, Amidi M, Hennink WE, et al. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation. J Control Release. 2015; 203: 16-22.
Fang RH, Hu CMJ, Luk BT, Gao WW, Copp JA, Tai YY, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014; 14: 2181-8.
Morishita M, Takahashi Y, Matsumoto A, Nishikawa M, Takakura Y. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials. 2016; 111: 55-65.
Mehta NK, Moynihan KD, Irvine DJ. Engineering new approaches to cancer vaccines. Cancer Immunol Res. 2015; 3: 836-43.
Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008; 38: 1404-13.
Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009; 373: 1033-40.
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9: 325-38.
Liang SJ, Li C, Zhang CL, Chen YS, Xu L, Bao CC, et al. CD44v6 monoclonal antibody-conjugated gold nanostars for targeted photoacoustic imaging and plasmonic photothermal therapy of gastric cancer stem-like cells. Theranostics. 2015; 5: 970-84.
Chen Q, Wang C, Zhang XD, Chen GJ, Hu QY, Li HJ, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2019; 14: 89-97.
Deng H, Zhang ZP. The application of nanotechnology in immune checkpoint blockade for cancer treatment. J Control Release. 2018; 290: 28-45.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23-34.
Cano-Mejia J, Burga RA, Sweeney EE, Fisher JP, Bollard CM, Sandler AD, et al. Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine. 2017; 13: 771-81.
Mi Y, Smith CC, Yang FF, Qi YF, Roche KC, Serody JS, et al. A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy. Adv Mater. 2018; 30: e1706098.
Wang C, Ye YQ, Hochu GM, Sadeghifar H, Gu Z. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 2016; 16: 2334-40.
Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015; 348: 56-61.
He CB, Duan XP, Guo NN, Chan C, Poon C, Weichselbaum RR, et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun. 2016; 7: 12499.
Zhang XD, Wang JQ, Chen ZW, Hu QY, Wang C, Yan JJ, et al. Engineering PD-1-presenting platelets for cancer immunotherapy. Nano Lett. 2018; 18: 5716-25.
Zhang XD, Wang C, Wang JQ, Hu QY, Langworthy B, Ye YQ, et al. PD-1 blockade cellular vesicles for cancer immunotherapy. Adv Mater. 2018; 30: e1707112.
京公网安备11010802044758号